Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire.
暂无分享,去创建一个
S. Rennard | R. Tal-Singer | P. Jones | H. Gelhorn | H. Müllerová | S. Menjoge | N. Karlsson | H. Wilson | D. Merrill | M. Tabberer
[1] The COPD Biomarkers Qualification Consortium Database: Baseline Characteristics of the St George's Respiratory Questionnaire Dataset. , 2017, Chronic obstructive pulmonary diseases.
[2] M. R. Siddiqui,et al. Global Initiative for Chronic Obstructive Lung Disease (GOLD) , 2017 .
[3] M. Cazzola,et al. A review of the most common patient-reported outcomes in COPD – revisiting current knowledge and estimating future challenges , 2015, International journal of chronic obstructive pulmonary disease.
[4] J. Wedzicha,et al. Minimal clinically important differences in pharmacological trials. , 2014, American journal of respiratory and critical care medicine.
[5] R. Casaburi,et al. The COPD Biomarker Qualification Consortium (CBQC) , 2013, COPD.
[6] M. Miravitlles,et al. Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement , 2012, International journal of chronic obstructive pulmonary disease.
[7] M. Miravitlles,et al. Beyond FEV 1 in COPD: a review of patient-reported outcomes and their measurement , 2012 .
[8] P. Calverley,et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study , 2011, The clinical respiratory journal.
[9] Liam Ck. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008 .
[10] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[11] P. Jones,et al. Outcomes and markers in the assessment of chronic obstructive pulmonary disease , 2006, European Respiratory Journal.
[12] P. Jones. St. George's Respiratory Questionnaire: MCID , 2005, COPD.